Haryana Has No Report On Coronil Efficacy: RTI Reply

Gurugram : The Haryana’s AYUSH Department, which purchased ₹2.72 crore-worth of Ramdev’s Ayurvedic COVID-19 medicine ‘Coronil’ in May this year, is not in possession of any test reports to establish its efficacy, an RTI reply has revealed.

The department also does not have a record of those who have recovered from the use of the ‘medicine’.

The proposal for the purchase of Coronil was referred by the office of Chief Minister Manohar Lal as per a letter by Haryana Medical Services Corporation Limited, the RTI reply revealed.

Due to paucity of funds with the AYUSH Department, the drug was bought with funds from the Haryana Corona Relief Fund.

The set of documents shared by the department, in reply to the RTI application by Panipat-based activist P.P. Kapoor, revealed that the technical panel of the AYUSH Department met on May 18 and approved the purchase saying the composition and strength of Coronil was as per the recommendations for immunity boosting and “maybe finalised and it may also be suitable for Corona patients”.

The State had 83,161 active cases on the said date and the panel approved to buy one lakh Coronil kits as mentioned in the quote given by Divya Pharmacy. Some of the ingredients of the tablet includes Giloy, Ashwagandha, Tulsi, Mulethi, Marich, and Choti Pipal.

  • Related Posts

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by week 1 and sustained through study end, alongside low rates of…

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    After substandard drug manufacturing, the state drug firms are once again under the scanner of the central government for manufacture and sale of unapproved fixed dose combination (FDC) drugs which…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise